+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Overall quality of life (QoL) is not meaningfully affected by severity of pegylated liposomal doxorubicin (PLD)-associated palmar-plantar erythrodysesthesia (PPE) among women with metastatic breast cancer

Overall quality of life (QoL) is not meaningfully affected by severity of pegylated liposomal doxorubicin (PLD)-associated palmar-plantar erythrodysesthesia (PPE) among women with metastatic breast cancer

Journal of Clinical Oncology 23(16_Suppl): 788-788

NlmCategory="UNASSIGNED">788 Background: Chemotherapy-associated toxicities such as anemia and neurotoxicity are evaluated using toxicity-specific instruments such as the FACT-AN and the FACT-NTX. PLD is a new chemotherapeutic agent demonstrated clinical efficacy in metastatic breast cancer both as a first-line agent (O'Brien Ann of Oncology 2004) and for taxane-refractory disease (Keller JCO 2004). Its most common toxicity is PPE (rates of severe [Grade 3-4] toxicity: 17% and 19%, respectively). We evaluated the utility of a commonly used QOL instrument to evaluate PPE impact among metastatic breast cancer patients who participated in recent RCTs with PLD. All PLD-treated patients in the first-line (n=150) and taxane-refractory (n=254) RCTs completed a general cancer-related QOL instrument, the European Organization for Research and Treatment of Cancer QLQ-30 at baseline and prior to subsequent chemotherapy cycles with PLD during the course of the trial. Mean QLQ-30 scores for PLD-treated patients (1st line and taxane-refractory RCTs) were similar regardless of whether the patient developed severe PPE or not at all. (Table 1, *p<0.05) Conclusions: PPE does not appear to meaningfully impact overall patient reported QoL. Further research is needed to determine if a syndrome specific questionnaire for PLD-associated PPE is needed. [Figure: see text] [Table: see text].

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 058484974

Download citation: RISBibTeXText

PMID: 27945760

Related references

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70(2): 141-146, 2006

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 23(3): 244-249, 2015

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia. Gynecology and Minimally Invasive Therapy 7(1): 44-45, 2018

Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecologic Oncology 131(3): 683-688, 2014

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Annals of Oncology 18(7): 1159-1164, 2007

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer ChemoTherapy and Pharmacology 44(4): 303-306, 1999

The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia. European Journal of Gynaecological Oncology 30(4): 387-388, 2009

Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin. Tumori 95(6): 687-690, 2010

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecologic Oncology 103(1): 72-74, 2006

Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience. Oncology 73(3-4): 277-278, 2008

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer ChemoTherapy and Pharmacology 76(5): 1033-1039, 2016

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecologic Oncology 114(2): 219-224, 2009

Amifostine in the prevention of liposomal doxorubicin induced palmar-plantar erythrodysesthesia. Blood 98(11 Part 2): 309b, November 16, 2001

Palmar-plantar erythrodysaesthesia during pegylated liposomal doxorubicin treatment. Współczesna Onkologia 3: 164-167, 2011

Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study. Farmacia Hospitalaria 35(1): 46-47, 2011